Ardian acquires a majority stake at Sintetica.

Ardian, a world-leading private investment house, announces the signing of a binding agreement for the acquisition of a majority stake in Sintetica, a Swiss pharmaceutical company, to support its international expansion in line with the management team’s strategy. Financial terms were not disclosed. “We are excited to join forces with Sintetica and support the company in its next growth phase by investing in innovation and further improving product quality. Leveraging Ardian’s global network and consolidated experience in partnering with entrepreneurs and managers, we intend to support the company in the development of its strategic plan in continuity with the growth path already undertaken.”, Yann Chareton, Ardian Managing Director. Rothschild & Co, NCTM and Ludovici Piccone & Partners are advising Sintetica. Gattai Minoli Agostinelli Partners, Leopoldo Zambeletti, Gianni Origoni Grippo Cappelli & Partners and Gitti and Partners are advising Ardian.